Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

BD FacsLyric 510(k) cleared with FacsDuet sample prep system

January 2021—BD received FDA 510(k) clearance for the BD FacsLyric flow cytometer integrated with the BD FacsDuet sample preparation system. Physical integration between the two instruments allows technicians to load samples and reagents onto the BD FacsDuet and obtain results once the samples are acquired and analyzed on the BD FacsLyric. Data integration using the BD FacsLink middleware solution offers bidirectional communication between the instruments and connectivity with laboratory information systems.

Streck launches rapid, modular qPCR instrument

January 2021—Streck has launched its Zulu RT, a rapid, modular qPCR instrument. The instrument consists of four independent thermal modules. A user can operate any combination of modules­—one module for a small sample set, leaving other modules for other users, or up to four modules simultaneously for a large sample set. It can perform a 40-cycle, six-channel real-time PCR in less than 20 minutes.

COVID-19, flu combo test for home-collected samples

January 2021—The FDA authorized the first diagnostic test for at-home collection of patient samples to detect COVID-19 and influenza A and B. Quest Diagnostics’ RC COVID-19 +Flu RT-PCR Test for prescription use was authorized with Quest’s Self-Collection Kit for COVID-19 +Flu for individuals who are suspected of respiratory viral infection consistent with COVID-19 when home collection is determined to be appropriate by an individual’s health care provider.

Nova Biomedical blood glucose reference analyzer

January 2021—Nova Biomedical announced the availability of Nova Primary, a rapid blood glucose laboratory analyzer. Nova Primary fills the need for a glucose reference analyzer to replace the YSI Stat Plus 2300 Glucose and L-Lactate analyzer, which, as of July 2021, will no longer be supported by YSI, Inc.

Qiagen fully acquires NeuMoDx Molecular

January 2021—Qiagen has acquired the remaining 80.1 percent of NeuMoDx Molecular for $248 million in cash. The company purchased a 19.9 percent stake in NeuMoDx in 2018, along with the right to acquire the remaining stake. As part of the 2018 deal, Qiagen has distributed the NeuMoDx 288 and NeuMoDx 96 platforms in Europe and other markets outside the United States.

510(k)-cleared, CLIA-waived Accula Strep A test

January 2021—Mesa Biotech received 510(k) clearance and CLIA waiver from the FDA for its Accula Strep A test. The strep A cassette, for the molecular detection of group A Streptococcus bacterial nucleic acid, is cleared for diagnosing children and adults and provides results in 30 minutes at the point of care.

TechLab to supply ASRs for SARS-CoV-2

January 2021—TechLab has partnered with New River Valley COVID-19 Task Force to expand future COVID-19 testing capacity. Under the agreement, the New River Health District, headquartered in Christianburg, Va., secures access to TechLab’s analyte-specific reagents for SARS-CoV-2 for $7 to $9 per use.

CDx to identify NTRK fusions in solid tumors approved

January 2021—The Food and Drug Administration approved the next -generation sequencing­­­–based FoundationOne CDx test (Foundation Medicine) as a companion diagnostic to identify fusions in neurotrophic receptor tyrosine kinase genes NTRK1, NTRK2, and NTRK3 in DNA isolated from tumor tissue specimens from patients with solid tumors eligible for treatment with larotrectinib (Vitrakvi, Bayer Healthcare Pharmaceuticals).

FDA authorizes POC antibody test for COVID-19

January 2021—The FDA issued an emergency use authorization for the first serology antibody point-of-care test for COVID-19. The Assure COVID-19 IgG/IgM Rapid Test Device (Azure Biotech) was first authorized in July for emergency use by certain labs to help identify individuals with antibodies to SARS-CoV-2. The EUA has been reissued to authorize the test for POC use using fingerstick blood samples. The lateral flow assay is authorized for use with venous whole blood, serum, plasma, and fingerstick whole blood.

MARKETPLACE

TRENDING